Targeted therapy options for chondrosarcoma - a preclinical perspective

1. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologicpathologic correlation. Radiographics. 2013; 23(5),1245–1278.10.1148/rg.235035134Search in Google Scholar

2. Meijer D, De Jong D, Pansuriya TC et al.Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012; 51(10), 899–909.2267445310.1002/gcc.2197422674453Search in Google Scholar

3. Mavrogenis AF, Gambarotti M, Angelini A et al. Chondrosarcomas revisited. Orthopedics. 2012; 35(3),e379–e390.10.3928/01477447-20120222-30Search in Google Scholar

4. Van Maldegem AM, Bovee JV, Gelderblom H. Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clin. Sarcoma Res. 2014; 4,11.10.1186/2045-3329-4-11Search in Google Scholar

5. Frezza AM, Cesari M, Baumhoer D et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur. J. Cancer. 2015; 51(3),374–381.10.1016/j.ejca.2014.11.007Search in Google Scholar

6. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 2011; 17(17), 5546–5552.10.1158/1078-0432.CCR-10-26162167008421670084Open DOISearch in Google Scholar

7. Perez J, Decouvelaere AV, Pointecouteau T et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS ONE. 2012; 7(6),e32458.Search in Google Scholar

8. Rubin LL, De Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev. Drug Discov. 2006; 5(12),1026–1033.10.1038/nrd2086Search in Google Scholar

9. Suijker J, Oosting J, Koornneef A et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015; 6(14),12505–12519.10.18632/oncotarget.3723Search in Google Scholar

10. NCCN Guidelines Version 2.2019. Bone Cancer https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.Search in Google Scholar

11. Schuetze SM, Wathen JK, Lucas DR et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016; 122(6),868–874.10.1002/cncr.29858Search in Google Scholar

12. Van Oosterwijk JG, Van Ruler MA, Briaire-De Bruijn IH et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br. J. Cancer. 2013; 109(5),1214–1222.10.1038/bjc.2013.451Search in Google Scholar

13. Mccubrey JA, Steelman LS, Franklin RA et al. Targeting the RAF/MEK/ERK, PI3K/ AKT and p53 pathways in hematopoietic drug resistance. Adv. Enzyme Regul. 2007; 47,64–103.10.1016/j.advenzreg.2006.12.013Search in Google Scholar

14. Myers AP, Cantley LC. Targeting a common collaborator in cancer development. Sci. Transl. Med. 2010; 2(48),48ps45.10.1126/scitranslmed.3001251Search in Google Scholar

15. Perez J, Decouvelaere AV, Pointecouteau T et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS ONE. 2012; 7(6),e32458.10.1371/journal.pone.0032458Search in Google Scholar

16. Zhang YX, Van Oosterwijk JG, Sicinska E et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin. Cancer Res. 2013; 19(14),3796–3807.10.1158/1078-0432.CCR-12-3647Search in Google Scholar

17. Tiet TD, Hopyan S, Nadesan P et al. Constitutive Hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am. J. Pathol. 2006; 168(1),321–330.10.2353/ajpath.2006.050001Search in Google Scholar

18. Italiano A, Le Cesne A, Bellera C et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/ US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann. Oncol. 2013; 24(11),2922–2926.10.1093/annonc/mdt391Search in Google Scholar

19. Sun Y, Guo W, Ren T et al. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 2014; 5,e979.10.1038/cddis.2013.497Search in Google Scholar

20. Kostine M, Cleven AHG et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Modern Pathology advance online publication, 17 June 2016.10.1038/modpathol.2016.10827312065Search in Google Scholar